[HTML][HTML] Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: a randomized clinical trial
…, M Zaidan, CLT Le Tiec, CV Verstuyft… - JAMA internal …, 2021 - jamanetwork.com
Importance Severe pneumonia with hyperinflammation and elevated interleukin-6 is a common
presentation of coronavirus disease 2019 (COVID-19). Objective To determine whether …
presentation of coronavirus disease 2019 (COVID-19). Objective To determine whether …
[HTML][HTML] Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial
…, M Zaidan, CLT Le Tiec, CV Verstuyft… - The Lancet …, 2021 - thelancet.com
Background Patients with COVID-19 pneumonia have an excess of inflammation and
increased concentrations of cytokines including interleukin-1 (IL-1). We aimed to determine …
increased concentrations of cytokines including interleukin-1 (IL-1). We aimed to determine …
[HTML][HTML] Genetic determinants of response to clopidogrel and cardiovascular events
T Simon, C Verstuyft, M Mary-Krause… - New England journal …, 2009 - Mass Medical Soc
Background Pharmacogenetic determinants of the response of patients to clopidogrel
contribute to variability in the biologic antiplatelet activity of the drug. The effect of these …
contribute to variability in the biologic antiplatelet activity of the drug. The effect of these …
Practical recommendations for pharmacogenomics-based prescription: 2010 ESF–UB Conference on Pharmacogenetics and Pharmacogenomics
…, RHN Van Schaik, C Verstuyft… - …, 2011 - Future Medicine
The present article summarizes the discussions of the 3rd European Science Foundation–University
of Barcelona (ESF–UB) Conference in Biomedicine on Pharmacogenetics and …
of Barcelona (ESF–UB) Conference in Biomedicine on Pharmacogenetics and …
Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity
L Bodin, C Verstuyft, DA Tregouet, A Robert, L Dubert… - Blood, 2005 - ashpublications.org
The aim of the study is to explore the contribution of genetic factors related either to drug
metabolism (cytochrome P450 2C9) or to drug target (vitamin K epoxide reductase) to variability …
metabolism (cytochrome P450 2C9) or to drug target (vitamin K epoxide reductase) to variability …
Environmental and genetic factors associated with morphine response in the postoperative period
L Coulbault, M Beaussier, C Verstuyft… - Clinical …, 2006 - Wiley Online Library
Objective The aim of this study was to investigate the respective influence of genetic and
nongenetic factors on morphine dose requirements and adverse effects after colorectal surgery. …
nongenetic factors on morphine dose requirements and adverse effects after colorectal surgery. …
Sarilumab in adults hospitalised with moderate-to-severe COVID-19 pneumonia (CORIMUNO-SARI-1): An open-label randomised controlled trial
…, M Zaidan, CLT Le Tiec, C Verstuyft… - The Lancet …, 2022 - thelancet.com
Background Patients with COVID-19 pneumonia can have increased inflammation and
elevated cytokines, including interleukin (IL)-6, which might be deleterious. Thus, sarilumab, a …
elevated cytokines, including interleukin (IL)-6, which might be deleterious. Thus, sarilumab, a …
Clinical events as a function of proton pump inhibitor use, clopidogrel use, and cytochrome P450 2C19 genotype in a large nationwide cohort of acute myocardial …
…, E Drouet, G Mulak, V Bataille, J Ferrières, C Verstuyft… - Circulation, 2011 - Am Heart Assoc
Background— Clopidogrel requires metabolic activation by cytochrome P450 2C19 (CYP2C19).
Proton pump inhibitors (PPIs) that inhibit CYP2C19 are commonly coadministered with …
Proton pump inhibitors (PPIs) that inhibit CYP2C19 are commonly coadministered with …
Digoxin pharmacokinetics and MDR1 genetic polymorphisms
C Verstuyft, M Schwab, E Schaeffeler, R Kerb… - European journal of …, 2003 - Springer
Background The effect of MDR1 C3435T single nucleotide polymorphism (SNP) in exon 26
on digoxin pharmacokinetics has recently been challenged. Objective To clarify the …
on digoxin pharmacokinetics has recently been challenged. Objective To clarify the …
Human multidrug and toxin extrusion 1 (MATE1/SLC47A1) transporter: functional characterization, interaction with OCT2 (SLC22A2), and single nucleotide …
…, C Verstuyft… - American Journal …, 2010 - journals.physiology.org
renal elimination of a number of cationic compounds is thought to be mediated by the
organic cation transporter 2 (OCT2, SLC22A2), a drug uptake transporter expressed at the …
organic cation transporter 2 (OCT2, SLC22A2), a drug uptake transporter expressed at the …